Exchange: NASDAQ·Updated 06:09 PM EST
CTSO logo

CTSO Cytosorbents Corp

$4.19
$0.97
(18.91%)
Today
Closed $4.16
$0.0311
(0.75%)
After Hours
Reported EarningsNov 12
Mkt Cap$13.12M
Vol28,812.00

About CTSO

CytoSorbents Corp. engages in critical care immunotherapy, investigation, and commercialization of blood purification technology. Its product portfolio includes CytoSorb, ContrastSorb XL, HemoDefend, VetResQ, and DrugSorb. The company was founded by Joseph Rubin in August 1997 and is headquartered in Princeton, NJ.
53

Neutral Sentiment

How do you feel about CTSO?

Rayvio_News_Filter
$CTSO 💰 CytoSorbents announced a $6.25 million common stock financing, including a $4.0 million registered direct offering and $2.25 million of Avenue debt converted into stock, reducing total debt by $5.25 million to $12.25 million and extending maturity to July 1, 2028. Timely market event
hanovk68
$CTSO Their “cash-flow breakeven” looks like a case of astute financial engineering when you carefully analyze their balance sheet. I’m certainly not convinced that their financial situation is on the road to recovery and am not taking a long position at this point.
StocktwitsEarnings
$CTSO Q3 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.48 up 42.17% YoY • Reported revenue of $9.73M up 2.64% YoY

Advertisement|Remove ads.